(Q51902225)

17 April 2018

title

A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. (English)

1 reference

17 April 2018

randomized controlled trial

main subject

1 reference

Mark Pollack

1

1 reference

17 April 2018

Richard Mangano

2

1 reference

17 April 2018

Richard Entsuah

3

1 reference

17 April 2018

Evan Tzanis

4

1 reference

17 April 2018

Naomi M Simon

5

1 reference

17 April 2018

Ying Zhang

6

1 reference

17 April 2018

publication date

23 June 2007

1 reference

17 April 2018

published in

Psychopharmacology

1 reference

17 April 2018

volume

194

1 reference

17 April 2018

page(s)

233-242

1 reference

17 April 2018

issue

2

1 reference

17 April 2018

https://scigraph.springernature.com/pub.10.1007/s00213-007-0821-0

exact match

0 references

cites work

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0821-0

Quality of life in panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0821-0

Multicenter collaborative panic disorder severity scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0821-0

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0821-0

Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00213-007-0821-0

21 January 2018

12 December 2020

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0821-0

Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias

21 January 2018

1 reference

12 December 2020

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

12 December 2020

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

1 reference

12 December 2020

Neuroanatomical hypothesis of panic disorder, revised

1 reference

12 December 2020

The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication

1 reference

12 December 2020

Panic disorder. Pathophysiology and drug treatment

1 reference

12 December 2020

Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial

1 reference

12 December 2020

Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study

1 reference

12 December 2020

Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study

1 reference

12 December 2020

WCA recommendations for the long-term treatment of panic disorder.

1 reference

12 December 2020

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

12 December 2020

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder

1 reference

12 December 2020

Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study

1 reference

12 December 2020

Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care

1 reference

12 December 2020

A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder

1 reference

12 December 2020

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

12 December 2020

Sertraline treatment of panic disorder: results of a long-term study

1 reference

12 December 2020

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

12 December 2020

Differential physiological effects of a low dose and high doses of venlafaxine in major depression

1 reference

12 December 2020

Desipramine in agoraphobia with panic attacks: an open, fixed-dose study.

1 reference

12 December 2020

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

12 December 2020

Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial

1 reference

12 December 2020

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group

1 reference

12 December 2020

Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation

1 reference

12 December 2020

Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association

1 reference

12 December 2020

Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety

1 reference

12 December 2020

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

12 December 2020

Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study

1 reference

12 December 2020

Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study

1 reference

12 December 2020

Bupropion sustained release for panic disorder.

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Dose-response relationship with venlafaxine

1 reference

12 December 2020

The effect of citalopram in panic disorder

1 reference

12 December 2020

Venlafaxine treatment of panic disorder: a case series.

1 reference

12 December 2020

Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study

1 reference

12 December 2020

Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

The epidemiology of panic disorder and agoraphobia in Europe

1 reference

12 December 2020

Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine

1 reference

12 December 2020

Low-dose venlafaxine treatment in panic disorder

1 reference

12 December 2020

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

1 reference

12 December 2020

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

12 December 2020

Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group

1 reference

12 December 2020

Panic disorder: impact on quality of life.

1 reference

12 December 2020

The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study

1 reference

12 December 2020

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

12 December 2020

Understanding and treating panic disorder in the primary care setting.

1 reference

12 December 2020

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

1 reference

12 December 2020

A rating scale for depression

1 reference

12 December 2020

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

12 December 2020

Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.

1 reference

12 December 2020

Long-term follow-up after a drug trial for panic disorder

1 reference

12 December 2020

Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.

1 reference

12 December 2020

10.1007/S00213-007-0821-0

Identifiers

DOI

1 reference

17 April 2018

PubMed ID

17589833

1 reference

17 April 2018